Mahruba Sultana Niloy, Md. Salman Shakil, Md. Meharab Hassan Alif and Rhonda J. Rosengren* Pages 8098 - 8115 ( 18 )
Approximately 85% of all lungs cancer cases are classified as non-small cell lung cancer (NSCLC). Kirsten rat sarcoma (KRAS) viral oncogene homolog mutations frequently occur in NSCLC patients resulting in a decreased overall survival. Additionally, currently used chemotherapeutic drugs lack selectivity,and patients experience side effects. Therefore, potent therapeutic agents are urgently needed for these patients. Plant- based compounds could be a potential option to treat KRAS-mutated NSCLC. These compounds are reported to be effective against the KRAS-linked up-stream and downstream signaling pathways that are directly or indirectly linked with cell proliferation, division, and apoptosis. Additionally, plant phytochemicals also suppressed different cell cycle phases of KRAS-mutant NSCLC cells. Furthermore, phytochemicals have a wider therapeutic index compared to chemotherapeutic drugs. Therefore, phytochemicals could benefit NSCLC patients as sole agents or as a combination therapy with approved chemotherapies. The current review aims to summarize the potential benefit of natural compounds in KRAS-mutant NSCLC.
KRAS, NSCLC, phytochemicals, cell signaling, cell cycle, and apoptosis.
Dept. of Biochemistry and Molecular Biology, Jahangirnagar University, Dhaka, Dept. of Pharmacology and Toxicology, University of Otago, Dunedin, Dept. of Biochemistry and Molecular Biology, Jahangirnagar University, Dhaka, Dept. of Pharmacology and Toxicology, University of Otago, Dunedin